Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 283

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Betibeglogene Autotemcel Gene Therapy for Non–β 0 /β 0 Genotype β-Thalassemia

Open access
Locatelli, Franco, Thompson, Alexis A., Kwiatkowski, Janet L., Porter, John B., Thrasher, Adrian J., Hongeng, Suradej, Sauer, Martin G., Thuret, Isabelle, Lal, Ashutosh, Algeri, Mattia, Schneiderman, Jennifer, Olson, Timothy S., Carpenter, Ben, Amrolia, Persis J., Anurathapan, Usanarat, Schambach, Axel, Chabannon, Christian, Schmidt, Manfred, Labik, Ivan, Elliot, Heidi, Guo, Ruiting, Asmal, Mohammed, Colvin, Richard A., Walters, Mark C.·2022·New England Journal of Medicine

Abstract

BACKGROUND: ) gene. METHODS: genotype. Patients underwent myeloablation with busulfan (with doses adjusted on the basis of pharmacokinetic analysis) and received beti-cel intravenously. The primary end point was transfusion independence (i.e., a weighted average hemoglobin level of ≥9 g per deciliter without red-cell transfusions for ≥12 months). RESULTS: ) was 8.7 g per deciliter (range, 5.2 to 10.6) in patients who had transfusion independence. The safety profile of beti-cel was consistent with that of busulfan-based myeloablation. Four patients had at least one adverse event that was considered by the investigators to be related or possibly related to beti-cel; all events were nonserious except for thrombocytopenia (in 1 patient). No cases of cancer were observed. CONCLUSIONS: genotype, including those younger than 12 years of age. (Funded by Bluebird Bio; HGB-207 ClinicalTrials.gov number, NCT02906202.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2113206

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 283

Metadata

Authors
Locatelli, F., Thompson, A. A., Kwiatkowski, J. L., Porter, J. B., Thrasher, A. J., Hongeng, S., Sauer, M. G., Thuret, I., Lal, A., Algeri, M., Schneiderman, J., Olson, T. S., Carpenter, B., Amrolia, P. J., Anurathapan, U., Schambach, A., Chabannon, C., Schmidt, M., Labik, I., Elliot, H., Guo, R., Asmal, M., Colvin, R. A., & Walters, M. C.
Venue
New England Journal of Medicine
Published
2022-02-03
Volume
386
Issue
5
Pages
415-427
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4200123108
Cited by
283
References
34
FWCI
17.23
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Betibeglogene Autotemcel Gene Therapy for Non–β 0 /β 0 Genotype β-Thalassemia. https://app.cochat.ai/papers/10.1056/nejmoa2113206
The paper
Locatelli, F., Thompson, A. A., Kwiatkowski, J. L., Porter, J. B., Thrasher, A. J., Hongeng, S., Sauer, M. G., Thuret, I., Lal, A., Algeri, M., Schneiderman, J., Olson, T. S., Carpenter, B., Amrolia, P. J., Anurathapan, U., Schambach, A., Chabannon, C., Schmidt, M., Labik, I., . . . Walters, M. C. (2022). Betibeglogene Autotemcel Gene Therapy for Non–β 0 /β 0 Genotype β-Thalassemia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2113206

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.